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Novel therapies targeting immune checkpoint molecules have redefined the treatment 
of cancer at advanced stages and brought hope to millions of patients worldwide. 
Monoclonal antibodies targeting immune-inhibitory receptors often lead to complete 
and objective responses as well as to durable progression-free survival where all other 
therapeutic approaches fail. Yet, many tumors show significant resistance to checkpoint 
blockade through mechanisms that are only starting to come to light. An alluring alter-
native strategy to reinvigorate anticancer immune responses comes from the emerging 
field of immuno-metabolism. Over the past few years, numerous studies revealed that 
many well-known metabolic playmakers also serve as critical checkpoints in immune 
homeostasis and immunity against tumors. Here, we survey recent insights into the 
intimate and intertwining links between T cell metabolic programs and environmental 
cues in the tumor milieu. Transferring these new findings from the bench to the bedside 
may soon entirely re-shape the field of cancer immunotherapy and significantly improve 
the lives of patients.
Keywords: metabolic checkpoints, immune checkpoints, cancer immunotherapy, PD-1, checkpoint blockade, 
mammalian target of rapamycin pathway
inTRODUCTiOn
Immunotherapy has become a paradigm-shifting approach showing unmatched efficacy in patients 
with advanced malignancies. Targeting immune regulatory receptors, such as CTLA-4, PD-1, and 
PD-1 ligand (PD-L1), leads to spectacular clinical responses (1). Unfortunately, the success of these 
treatments is often limited to minor cohorts of patients. This calls for the development of alternative 
strategies for reinvigorating anticancer immunity. Recently, research into immuno-metabolism has 
emerged as an extraordinarily vibrant and productive area of study that is likely to become a launch-
pad for novel therapeutic approaches (2, 3). Over the past few years, the immunological community 
has witnessed a veritable Cambrian explosion of remarkable studies identifying the critical metabolic 
programs and checkpoints in the activation, differentiation, and migration of immune cells (2, 4). 
This research has illuminated the metabolic requirements for successful T cell-mediated effector 
responses and memory T cell generation in cancer. Furthermore, several groups have revealed the 
complex effects of multiple micro-environmental factors on T cell functionality in the tumor (5, 6). 
For instance, the pleiotropic roles of oxygen tension in the regulation of anticancer immunity are 
now coming to light.
Importantly, pathways controlling T cell responses to external challenges often converge on the 
same limited set of enzymes, transcription factors, and signaling complexes serving as metabolic 
checkpoints (7, 8). This highlights the elegant simplicity and dazzling complexity of T cell biology. 
2Shevchenko and Bazhin Targeting Metabolism for Cancer Immunotherapy
Frontiers in Immunology | www.frontiersin.org August 2018 | Volume 9 | Article 1816
Untangling these immuno-metabolic nodes will be essential for 
the rational design of future therapies for cancer.
iMMUnO-MeTABOLiC CHeCKPOinTS  
in T CeLL DiFFeRenTiATiOn AnD 
FUnCTiOn
Metabolic changes occur throughout the lifespan of a T cell and 
provide the essential energetic currency and building blocks 
to help the T cell meet the emerging needs (4). Effective T cell 
responses against tumors strongly depend on the differentiation 
pathways taken up by individual CD4+ and CD8+ T cells upon 
their interaction with tumor antigens (9). The lineage commit-
ment of stimulated T  cells depends on the integration of the 
plethora of environmental cues and cell-intrinsic signals during 
activation, initial proliferation rounds, development of effector 
functions, and until final differentiation steps (2, 10).
Throughout their developmental path, T  cells must strike a 
balance between increasing energy demands and a growing need 
for substrates to maintain their functionality and proliferation 
(2). Naive or quiescent T cells rely mainly on oxidative phospho-
rylation (OXPHOS), a highly efficient pathway for generating 
ATP from glucose. Upon activation, however, a switch to aerobic 
glycolysis takes place. In this rather inefficient process, only 
two ATP molecules are produced per each molecule of glucose. 
Switching to aerobic glycolysis might appear very inefficient, due 
to the low ATP/glucose ratio. Yet, at the same time, aerobic gly-
colysis yields a higher number of building blocks for anabolism. 
Importantly, the glycolytic switch is also essential for T cells to 
acquire diverse effector functions (e.g., production of IL-2, IFN-γ, 
etc.), since it relieves the blockade of IFN-γ mRNA translation by 
the glycolytic enzyme GAPDH (11).
The metabolic switch upon T  cell activation is governed by 
a plethora of transcription factors and signaling pathways. 
Together, TCR engagement, costimulation, and cytokine signal-
ing boost glycolysis by upregulating the expression of nutrient 
transporters (such as the Glut1 glucose importer) and activating 
the central metabolic regulator mammalian target of rapamycin 
(mTOR) complex (12–14). mTOR drives the development of all 
the effector T  cell subsets but hampers peripheral Treg induc-
tion. This can be accounted for the requirement of intensified 
glycolysis during effector T  cell expansion, while Treg cells 
primarily deploy OXPHOS and oxidation of fatty acids. mTOR 
comprises two distinct complexes, mTORC1 and mTORC2, 
and orchestrates cellular responses to changes in nutrient levels 
and energy status (15). Costimulation via CD28 activates PI3K 
recruiting 3-phosphoinositide-dependent protein kinase-1 and 
Akt, which, in turn, activates mTOR. This pathway leads to the 
quick upregulation of Glut1 expression and to its increased trans-
port to the plasma membrane. The rapid intensification of glucose 
import is critical for efficient T cell activation, clonal expansion, 
and survival.
Of note, a study by Macintyre et al. (16) suggested that Glut1 
is only indispensable for the differentiation of Th1, Th2, and 
Th17 cells, but not CD8+ T cells or Tregs. A plausible explanation 
might be coming from recent proteomic studies indicating that 
Glut1 and Glut3 protein levels are comparable in CD8+ T cells 
(17). Therefore, glucose transporters can act in a somewhat 
redundant fashion to meet the demands of T cells for glucose.
The multifaceted role of glucose uptake in Treg biology 
has recently been further elucidated in a study by Rathmell 
and colleagues who identified toll-like receptor (TLR) signals 
that drive Treg cell proliferation via PI(3)K–Akt–mTORC1 
signaling, which intensifies glycolysis and glucose import by 
Glut1 (18). Conversely, TLR-induced mTORC1 signaling 
also diminished the ability of Tregs to suppress effector T cell 
proliferation. In line with previous studies, the transcription 
factor Foxp3 dampened the effects of PI(3)K–Akt–mTORC1 
signaling to hamper glycolysis and anabolism while boosting 
OXPHOS and catabolic pathways. Likewise, although Glut1 
expression promoted Treg expansion, it also reduced their 
suppressive activity and Foxp3 expression. This indicates that 
Treg cells might occasionally switch to aerobic glycolysis and 
expand when they receive inflammatory signals, and subse-
quently switch back to FAO and OXPHOS to achieve maximal 
suppressive potency. These findings further highlight glycolysis 
as a critical metabolic axis in maintaining the immunological 
balance. Therefore, glycolytic enzymes and nutrient transport-
ers represent attractive targets for future immuno-metabolic 
therapies of cancer. Specifically, administration of glucose 
uptake inhibitors or Glut knockdown in adoptively transferred 
cells could be instrumental for pushing antitumor T  cell dif-
ferentiation toward long-lived memory cell lineage for the 
generation of enduring antitumor immunity (9, 19).
Migration of activated Treg cells to the site of inflammation is 
crucial for their immune-inhibitory function (20). Kishore et al. 
(21) have studied the metabolic needs for migratory Treg. They 
demonstrated that glycolysis strongly promotes Treg migration 
and is triggered by a PI3K–mTORC2-mediated pathway driving 
the activation of the enzyme glucokinase. These findings also sug-
gest a new attractive strategy to avert Treg infiltration into tumors 
by manipulating their metabolic programs.
The transcription factors c-Myc and hypoxia-inducible 
factor-1α (HIF-1α) coordinately activate the genes required for 
the vigorous proliferation of effector T cells during clonal expan-
sion (22, 23). Importantly, both Myc and HIF-1α are under the 
control of the mTOR complex. C-Myc promotes the expression 
of enzymes involved in aerobic glycolysis and glutaminolysis 
and fine-tunes these metabolic pathways to the biosynthesis of 
lipids, amino acids, and nucleic acids. HIF-1α mediates T  cell 
responses to oxygen levels and also promotes glucose uptake and 
breakdown (24). Thus, the same transcription master regulators 
that control such fundamental processes as cell proliferation 
and cellular response to oxygen tension are also responsible for 
adjusting T cell metabolism to emerging needs. This underscores 
the startling universality and efficiency of these most funda-
mental mechanisms of epigenetic regulation and indicates that a 
robust reprogramming of antitumor T cell metabolism might be 
achieved by only targeting a few select molecules.
The dichotomy between glycolysis versus OXPHOS and 
FAO is not only central to the control of T  cell activation and 
effector function but is also decisive in the fate of differentiating 
T  cells. Most importantly, in precursors of long-lived memory 
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cells, OXPHOS and FAO are engaged to balance out the effects 
of aerobic glycolysis (25). A pivotal role for mitochondria (26) 
in these cells is manifest in the dynamics of their ultrastructure. 
In memory T  cells, mitochondrial cristae fuse into elaborate 
networks, while mitochondria in effector T cells exhibit extensive 
fission. The functionality of mature memory cells is also sustained 
by the higher biomass and spare respiratory capacity of their 
mitochondria through IL-15-driven upregulation of carnitine 
palmitoyl-transferase. This enzyme drives FAO and engenders 
stronger and more protracted OXPHOS and glycolysis upon 
restimulation.
Importantly, a wealth of recent evidence illuminates the pos-
sibilities to improve clinical responses to immune checkpoint 
inhibitors by combining these therapies with modulation of 
metabolic pathways. For instance, a series of elegant studies by 
Chi and colleagues (7, 27, 28) have demonstrated the intimate 
interplay between immune and metabolic checkpoints in T cell 
differentiation. Specifically, mTORC1 signaling was established as 
a key “rheostat” in Treg cell function (28). Treg-intrinsic disrup-
tion of mTORC1 led to a drastic slump in Treg suppressive activity 
and launched a deadly early-onset inflammatory disease. Raptor/
mTORC1 signaling in Tregs boosted the metabolism of choles-
terol and lipids, while the mevalonate pathway proved essential 
for orchestrating Treg proliferation and upregulated expression 
of the checkpoint molecules CTLA4 and ICOS. Another study by 
the same group highlighted the role of autophagy in the lineage 
stability and survival of Treg cells (29). Treg cell-specific defi-
ciency in Atg7 or Atg5, two pivotal genes in autophagy, resulted in 
a diminished Treg compartment, improved antitumor immunity, 
and development of inflammatory disorders. Autophagy kept in 
check mTORC1, c-Myc, and glycolytic enzymes, thereby coupling 
environmental signals to metabolic homeostasis.
MeTABOLiC COMPeTiTiOn in THe 
TUMOR MiCROenviROnMenT
Recent studies have directly linked T  cell metabolism, T  cell 
exhaustion, and antitumor immunity. In the tumor, the scarcity 
of nutrients can profoundly affect cell proliferation, survival, 
and functionality. T  cell-infiltrating tumors become enmeshed 
into teeming metabolic networks established within the hostile 
microenvironment and are forced to face ruthless competition for 
nutrients. Cancer cells can express various enzymes that deprive 
T  cells of critical substrates and produce immune-inhibitory 
metabolites (Figure 1). For instance, many tumors contain large 
amounts of indoleamine 2,3-dioxygenase (IDO), an enzyme that 
eliminates tryptophan from the microenvironment and hampers 
T cell proliferation (30). Of note, despite the significant efficacy 
of IDO inhibitors in mouse models of cancer, these compounds 
have shown no measurable antitumor efficacy in clinical set-
tings (31). The potential advantages and pitfalls of therapeuti-
cally exploiting the metabolic differences between normal and 
malignant cells have recently been comprehensively surveyed by 
Martinez-Outschoorn and coauthors (32).
In two pioneering studies, published side by side in Cell (5, 6), 
the groups of Susan Kaech and Erika Pearce reported that tumor 
cells outcompete T  cells for glucose, thereby dampening their 
effector function and evading immune destruction. Ho et al. (5) 
demonstrated that unperturbed glucose metabolism in T  cells 
is critical for TCR-induced Ca2+ flux. Extracellular glucose 
promoted accumulation of phosphoenolpyruvate, a glycolytic 
metabolite that inhibited sequestering of Ca2+ from the cytoplasm 
into the ER, thereby sustaining activation-induced Ca2+ flux 
and T cell effector function. Conversely, increased expression of 
the glycolysis gatekeeper hexokinase 2 in tumor cells facilitated 
tumor escape from CD4+ T cell-mediated immune surveillance, 
further corroborating the importance of metabolic competition 
between tumor-infiltrating lymphocytes (TILs) and tumor cells.
In the other study, Chang et al. (6) demonstrated that signaling 
through PD-L1 in tumor cells promotes glycolysis via activation 
of the AKT/mTOR pathway. Therapeutic blockade of PD-L1 
decreased glycolysis rate by triggering PD-L1 internalization, 
restored glucose levels in the microenvironment, and hindered 
tumor progression. These data provided a breakthrough in our 
understanding of the deeply intertwined metabolic and immune 
checkpoint signaling pathways and underscore the potential of 
future immune-metabolic therapies.
Conversely, rather than targeting the metabolism of tumor 
cells, Ho et al. (5) put forward an alternative strategy to reinforce 
T cell function by artificially increasing PEP levels in adoptively 
transferred tumor-reactive T  cells. PEP carboxykinase (PCK1) 
catalyzes conversion of oxaloacetate into PEP. Overexpression of 
PCK1 in transferred T cells allowed the authors to restore TCR-
driven Ca2+ flux and anticancer T  cell activity, thus overriding 
the effects of low glucose levels in the tumor microenvironment. 
Overall, these reports provided inspiring examples of repro-
gramming T cell metabolism to enhance the efficacy of adoptive 
cell therapies for cancer and spawned many further studies 
exploring T cell metabolic dysfunction in the tumor.
For instance, the latest works by Delgoffe and colleagues shed 
new light on various aspects of T  cell metabolism in cancer. 
For example, Scharping et  al. (33) reported a continuous loss 
of mitochondrial mass and functionality in tumor-infiltrating 
T cells, which proved restricted to the tumor milieu and was not 
a mere consequence of activation. Due to chronic Akt signaling, 
TILs showed dwindling expression of PPAR-gamma coactiva-
tor 1α (PGC1α), a vital factor in mitochondrial biogenesis. 
Reprogramming TILs through forced expression of PGC1α rein-
vigorated their metabolic and effector function. Interestingly, in a 
study by Wherry and colleagues (34), PD-1 was shown to inhibit 
PGC1α and thereby serve as a dominant-negative regulator of 
glycolysis in activated T cells.
More recently, it has been reported that T  cell activation 
leads to a rapid glycolytic switch independently of transcription, 
translation, costimulation through CD28, or Akt signaling and 
without an increase in glucose uptake or in the activity of glycolytic 
enzymes (35). Instead, TCR engagement enhances activation of 
pyruvate dehydrogenase kinase 1 (PDHK1), thereby hampering 
import of pyruvate into mitochondria and promoting its cleavage 
into lactate. Intriguingly, inhibiting PDHK1 revealed that the early 
glycolytic switch is required for immediate cytokine production 
but not for cytotoxicity. Recently, Menk et al. (36) demonstrated 
that ligation of 4-1BB (a costimulatory molecule highly expressed 
FigURe 1 | Rapidly proliferating tumor cells avidly consume nutrients from the microenvironment, thereby outcompeting T cells in a contest for metabolic fitness. 
Increased activity of hypoxia-inducible factor-1α (HIF-1α) driven by tumor hypoxia further intensifies glycolysis and exacerbates the paucity of glucose in the milieu. 
This results in T cell deprivation of essential fuel for their effector function, resulting in a thwarted antitumor immune response. PD-1 signaling in T cells dampens 
their glycolytic activity and proliferation, while PD-1 ligand (PD-L1) ligation leads to opposite effects in cancer cells.
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on exhausted T  cells) provides metabolic support to tumor-
infiltrating T  cells by enhancing their mitochondrial capacity 
and engaging PGC1α-mediated pathways. Remarkably, 4-1BB 
stimulation combined with PD-1 blockade resulted in robust 
antitumor immunity. This study further highlights the potential 
of combinatorial strategies targeting immune-metabolic check-
points for reshaping the immune-inhibitory tumor milieu.
OXYgen SenSing
The transcription factor HIF-1α is a critical driver of effector 
T cell responses, which is particularly important for the differen-
tiation of CD4+ Th17 cells (37), CD8+ T cell effector function (22), 
and interferon IFN-γ production by T regulatory cells. Besides 
governing the glycolytic switch in Th17 cells, HIF-1α also trans-
activates the gene encoding the Th17 master transcription factor 
RORγt (37). It has been demonstrated that HIF-1α-mediated 
T cell response to hypoxia upregulates the expression of Glut1, 
as well as glycolytic enzymes, and therefore strongly affects 
T cell differentiation and function. For instance, Cretenet et al. 
(38) demonstrated that hypoxia significantly enhances Glut1 
upregulation in response to TCR stimulation. Furthermore, 
Glut1hi T  lymphocytes displayed more pronounced Th1 effec-
tor phenotype and higher proliferation rate than their Glut1lo 
counterparts, both under normoxic and hypoxic conditions. 
Therefore, enhancing glucose uptake in adoptively transferred 
T  cells might allow for efficiently countering hypoxia-driven 
immune suppression.
The activity of HIF-1a is tightly controlled by the oxygen-
sensing prolyl-hydroxylase (PHD) proteins. Under normoxia, 
PHDs hydroxylate HIF-1α and HIF-2α, thereby targeting them 
for degradation. In their recent study, Restifo and colleagues 
(39) found that expression of PHDs in T cells ensures local toler-
ance for harmless antigens in the lung but markedly facilitates 
the seeding of circulating tumor cells. In line with their role as 
HIF-1α inhibitors, PHDs limited pulmonary Th1 responses, pro-
moted Treg cell induction, and dampened CD8+ T cell function. 
Importantly, it was shown that the effects of the PHD enzymes 
are primarily mediated by the repression of HIF-driven glycolytic 
metabolism.
Specifically, T  cells stimulated in TGF-β-containing media 
exhibited a PHD-dependent reduction of glycolytic activity. On 
the other hand, PHD-deficient CD4+ T  cells exhibited acceler-
ated uptake of glucose and switched to an anaerobic metabolic 
program. PHD proteins also restrained glycolysis in CD8+ T cells. 
Remarkably, targeting mTOR-driven glycolytic metabolism with 
rapamycin and 2-deoxyglucose completely blocked spontaneous 
Th1 development and partially restored iTreg cell differentiation 
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in PHD-deficient T  cells. Hence, oxygen sensing appears to 
coordinate transcriptional and metabolic programs driving the 
differentiation of Th1 and iTreg cells. Recent clinical studies have 
demonstrated the efficacy and overall safety of PHD inhibitors in 
patients with anemia and other hypoxia-driven pathologies (40). 
However, the complexity and the near-universal nature of the 
HIF pathways necessitate thorough evaluation of adverse effects. 
Collectively, targeting PHD proteins and other links in oxygen 
sensing is an alluring strategy to tilt the balance between immune 
activation and immune suppression in the tumor.
COnCLUSiOn AnD FUTURe DiReCTiOnS
Metabolism is integral to every biological process. The immune 
system largely consists of mobile cells that patrol the body and 
need to adapt to diverse challenging environments. This requires 
tight and sophisticated coordination of their bioenergetic 
machinery with their homeostatic pathways and effector func-
tions. Here, we summarized the latest studies shedding light onto 
the specific roles of particular substrates, enzymes, and metabolic 
regulators in T cell differentiation and antitumor activity. Despite 
the startling progress that has been made in the field within just 
a few years, several critical questions remain unanswered. For 
instance, the timing and the mutual causality of the major meta-
bolic switches during T cell differentiation remain largely elusive. 
Specifically, it will be crucial to capture the exact moments when 
differentiating T cells pass through a given metabolic checkpoint 
and how this affects the identity and the fate of a T cell. Likewise, 
further research is necessary to gain a more integrative view of 
how intratumoral T cells are affected by hypoxia and relentless 
metabolic competition imposed by cancer cells.
In the same vein, there is a pressing need to assess the thera-
peutic efficacy of a broader spectrum of genetic modifications 
targeting diverse metabolic regulators and oxygen sensors in 
adoptively transferred T cells. Importantly, the ubiquity of many 
metabolic pathways calls for careful target selection and cautious 
design of therapeutic regimens based on highly specific small 
molecule inhibitors. Overall, future immune-metabolic therapies 
have all the potential to make a critical difference for patients 
suffering from otherwise untreatable cancers.
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